Lithuania Pioneers ‘Teranostics’ – A revolution in Personalized Cancer Treatment
Table of Contents
A groundbreaking approach to cancer treatment, known as teranostics, is gaining traction in Lithuania, offering new hope for improved patient outcomes.
A leading cancer center director recently hailed the advancement of teranostics into clinical practice, noting its potential to significantly enhance patient survival rates. The innovative method represents a paradigm shift in oncology, moving beyond traditional treatment protocols toward highly individualized care.
Understanding Teranostics: Seeing is Believing
Teranostics, a fusion of “therapy” and “diagnostics,” is a next-generation approach to personalized medicine. Unlike conventional cancer treatments determined solely by cancer type,teranostics delves deeper,analyzing the precise number and location of cancer cells within a patient’s body.
“This means that medications are selected not only after determining the type of cancer and whether the patient has it, but also by establishing how many cells are in the person and where those cells are located,” explained a senior official at the National Cancer Center (NCC).”Based on this information, treatment is tailored to the individual patient.”
A core principle of teranostics is the ability to both visualize and treat cancer simultaneously. “We treat what we see, and we see what we treat,” the official stated. “This provides continuous monitoring of treatment progress, offering patients and physicians valuable insights into efficacy.”
How Teranostics Works: The ‘Key and Lock’ Principle
The efficacy of teranostics hinges on the use of radioligands – radioactive substances that function on a “key and lock” principle. Thes substances, administered to the patient, specifically target cancer cells, binding to them with remarkable precision.
“the drugs administered to the patient find those cells that match the ‘key’ – which are cancer cells,” the official elaborated. Importantly, after delivering their therapeutic payload, these radioactive materials naturally neutralize and decay, eliminating the risk of long-term drug circulation within the body.
“It may sound like science fiction to introduce a drug to a patient that finds cancer cells, destroys cancer cells, and then neutralizes itself,” the official acknowledged. “Though, this is a science-based solution, and it is indeed no longer science fiction.”
Access and Rising Cancer Rates in Lithuania
Lithuania has already approved one teranostics-based drug, making it available to patients starting March 1st. This progress comes as the country faces a growing incidence of cancer, driven by an aging population and improvements in diagnostic capabilities.
Data reveals a critically important increase in cancer diagnoses: the total number of individuals living with a cancer diagnosis has risen significantly in recent years.
Why is this happening? Lithuania, like many European nations, is experiencing an aging population, a key factor in rising cancer rates. Improved diagnostic tools also contribute to the increase, as more cases are detected earlier.
Who is involved? The National Cancer Centre (NCC) is central to the implementation of teranostics, with a senior official providing key insights. Cancer center directors are also advocating for the new approach. Patients are the ultimate beneficiaries.
What is teranostics? Teranostics is a personalized cancer treatment approach that combines diagnosis and therapy. It uses radioligands to target and treat cancer cells while simultaneously monitoring treatment progress.
how did it end? As of March 1st, Lithuania has approved its first teranostics-based drug, making it available to patients. The country is responding to a growing cancer incidence rate with this innovative treatment.
Related reading
